Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

Biocon advanced 3.17% to Rs 328.75 after Biocon Biologics (BBL) secures multiple market access agreements in the United States for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab), ...

Biocon Biologics (BBL), subsidiary of Biocon, today announced the Company has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab). The ...

From the column: "In Minnesota, the Legislature has a lot of power to effect change for Medical Assistance patients." ...

Cigna (($CI)) has held its Q1 earnings call. Read on for the main highlights of the call. Cigna Corporation’s recent earnings call highlighted a ...

Eighty-eight acres of the Cigna/Express Scripts/IBM property have been formally transferred to developer SHG Franklin Lakes LLC.

The state of Michigan has sued pharmacy benefit managers Express Scripts and Prime Therapeutics for anticompetitive behavior ...

Cigna Group on Friday reported a $1.3 billion profit for the first quarter of 2025, a sharp turnaround from a year-earlier ...

Michigan Attorney General Dana Nessel sued Express Scripts Inc. and Prime Therapeutics LLC, two pharmacy benefit managers ...

The Fourth Circuit Court of Appeals recently concluded that the U.S. Supreme Court’s decision in Coinbase Inc. v. Bielski is not limited ...

The company’s health services division Evernorth is doubling down on a reliable growth area: assuaging payer concerns around ...

ET on May 2Cigna is doubling down on its efforts to manage the challenges associated with GLP-1s through the launch of two ...